Metabolically Healthy Obesity
Open accessThe DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
Obesity contributes to reduced life expectancy, impaired quality of life, and disabilities, mainly in those individuals who develop cardiovascular diseases, type 2 diabetes, osteoarthritis, and cancer. However, there is a large variation in the individual risk to developing obesity-associated comorbid diseases that cannot simply be explained by the extent of adiposity. Observations that a proportion of individuals with obesity have a significantly lower risk for cardiometabolic abnormalities led to the concept of metabolically healthy obesity (MHO). Although there is no clear definition, normal glucose and lipid metabolism parameters—in addition to the absence of hypertension—usually serve as criteria to diagnose MHO. Biological mechanisms underlying MHO lower amounts of ectopic fat (visceral and liver), and higher leg fat deposition, expandability of subcutaneous adipose tissue, preserved insulin sensitivity, and beta-cell function as well as better cardiorespiratory fitness compared to unhealthy obesity. Whereas the absence of metabolic abnormalities may reduce the risk of type 2 diabetes and cardiovascular diseases in metabolically healthy individuals compared to unhealthy individuals with obesity, it is still higher in comparison with healthy lean individuals. In addition, MHO seems to be a transient phenotype further justifying therapeutic weight loss attempts—even in this subgroup—which might not benefit from reducing body weight to the same extent as patients with unhealthy obesity. Metabolically healthy obesity represents a model to study mechanisms linking obesity to cardiometabolic complications. Metabolically healthy obesity should not be considered a safe condition, which does not require obesity treatment, but may guide decision-making for a personalized and risk-stratified obesity treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Hyperplasia, referring to an increase in the number of adipocytes, is associated with an increase in subcutaneous fat volume and protective signals, and is associated with MHO (50).”
From Metabolic impact of endogenously produced estrogens by adipose tissue in females and males across the lifespan (2025) · cites this paper as [50]
The cited source says what the claim attributes to it.
In the citing paper
“On the contrary, hypertrophic adipocytes, in which existing adipocytes enlarge, is associated with increased dysfunction and MUHO (50), which contributes to IR and subsequent T2D (52, 53).”
From Metabolic impact of endogenously produced estrogens by adipose tissue in females and males across the lifespan (2025) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Abarca-Gómez, L., Abdeen, Z. A., Hamid, Z. A., Abu-Rmeileh, N. M., Acosta-Cazares, B., Acuin, C., Adams, R. J., Aekplakorn, W., Afsana, K., Aguilar-Salinas, C. A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32129-3 · Cited by 7,482
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Obesity: global epidemiology and pathogenesis
Blüher, M. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0176-8 · Cited by 5,126
Self-citationThe global obesity pandemic: shaped by global drivers and local environments
Swinburn, B. A., Sacks, G., Hall, K. D., McPherson, K., Finegood, D. T., Moodie, M. L., & Gortmaker, S. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60813-1 · Cited by 4,888
Cited by
Items 401–500 of 999
Pathophysiological hallmarks in type 2 diabetes heterogeneity (review)
Datta, D., Kundu, R., Basu, R., & Chakrabarti, P. (2024) · Diabetology International · doi:10.1007/s13340-024-00783-w · Cited by 12
“Although current obesity based classification system is inherently limited by stratification criteria and corresponding statistical parameters, it can yet provide an opportunity to help in tailored treatment through detail characterization of phenotypic heterogeneity [16, 57].”
Oral, A., Solmaz, İ., Koca, N., Topaloğlu, U. S., Demir, İ., Dündar, A. S., Kırık, A., BAŞCI, Ö. K., Şen, H., Binnetoglu, E., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082680 · Cited by 12
Adipose Tissue as a Target for Precision Medicine Approaches in Childhood Obesity
Cartwright, B. R., & Scherer, P. E. (2025) · Diabetes · doi:10.2337/dbi24-0044 · Cited by 10
Linear ubiquitination prevents lipodystrophy and obesity-associated metabolic syndrome
Hildebrandt, X., Veli, Ö., Hyoubi, A., Zinngrebe, J., Abdallah, A. T., Rodefeld, J., Hoffmann, A., Gardeweg, L., Kaya, Ö., Wagner, E., et al. (2025) · Science Advances · doi:10.1126/sciadv.adw2539 · Cited by 9
Self-citationPhenotyping obesity through a two-dimensional tree structure reveals cardiometabolic heterogeneity
Jia, X., Lin, H., Ding, Y., Hu, C., Wang, S., Li, M., Xu, Y. H., Xu, M., Huang, F., Shen, F., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102372 · Cited by 9
Lian, L., Liu, C., Zhou, X., Targher, G., Byrne, C. D., Zhang, Y., Qi, X., Jin, H., Zheng, M., & Liu, W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70271 · Cited by 10
“16 Furthermore, attempts to categorise obesity based on metabolic health — for such as distinguishing between metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUO) 17 have also encountered difficulties.”
InfluentialLiu, Y., Wu, X., Wang, Y., & Guo, Y. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03990-6 · Cited by 7
Ler, P., Li, X., Hassing, L. B., Reynolds, C. A., Finkel, D., Karlsson, I., & Aslan, A. K. D. (2022) · BMC Public Health · doi:10.1186/s12889-022-13082-3 · Cited by 9
“The National Cholesterol Education Program Adult Treatment Panel-III (NCEP ATP-III) criteria for MetS [32], previous literature [17, 21], and data availability guided the ascertainment of MHS in this study.”
BackgroundMethodWeight loss to disrupt type 2 diabetes
Alsaqaaby, M. S., & le Roux, C. W. (2023) · Diabetology International · doi:10.1007/s13340-023-00626-0 · Cited by 8
“Similarly, having a high BMI could lead to other metabolic functions in some populations like non-alcoholic steatohepatitis (NASH) [11] while causing no metabolic complications in other populations [13].”
BackgroundChen, J.-H., Zhang, J., Xia, Y., Li, J., Jia, Q., Zhang, Z., Jing, X., Xu, Y., Zou, L., Wang, L., et al. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00070 · Cited by 7
Physical activity in relation to metabolic health and obesity: The Feel4Diabetes study
Pelekanou, C., Anastasiou, C. A., Mavrogianni, C., Cardon, G., Liatis, S., Lindström, J., Moreno, L. A., Hilal, S., Rurik, I., Wikström, K., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15713 · Cited by 8
Association between dietary patterns and obesity: a longitudinal prospective cohort study
Tan, L.-J., Oh, S.-J., Ulzii, B. N., Lee, W., Hong, S. W., & Shin, S. (2024) · Public Health · doi:10.1016/j.puhe.2024.04.002 · Cited by 9
MCM proteins are up-regulated in placentas of women with reduced insulin sensitivity
Bandres‐Meriz, J., Sanz-Cuadrado, M. I., de Mendoza, I. H., Majali‐Martinez, A., Honeder, S. E., Cindrová‐Davies, T., Birner‐Gruenberger, R., Dalgaard, L. T., & Desoyé, G. (2024) · Bioscience Reports · doi:10.1042/bsr20240430 · Cited by 8
Saeed, S., Poulsen, L. L. C., Visnovska, T., Hoffmann, A., Ghosh, A., Wolfrum, C., Rønningen, T., Dahl, M. B., Wang, J., Çayır, A., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105653 · Cited by 9
“31,32 Exclusion criteria included participants under 18 years of age, those with chronic substance or alcohol misuse, smokers within the 12 months prior to surgery, individuals with acute in fl ammatory diseases, those taking glitazones as concomitant medication, patients with end-stage malignant…”
Self-citationThe liver-gut axis perspective: Exploring the pathogenesis of fatty liver
Yang, Z., Zhang, J., Liu, X., Chen, H., Duan, H., Wang, Q., Zhao, W., & Jin, L. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177822 · Cited by 8
Jones, J., Reneau, P. D., & dos Santos, J. M. (2021) · Medical Hypotheses · doi:10.1016/j.mehy.2021.110542 · Cited by 9
Diet-Dependent Changes of the DNA Methylome Using a Göttingen Minipig Model for Obesity
Feng, Y., Cirera, S., Taşöz, E., Liu, Y., Olsen, L. H., Christoffersen, B. Ø., Pedersen, H. D., Ludvigsen, T. P., Kirk, R. K., Schumacher-Petersen, C., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.632859 · Cited by 8
“These genes have been demonstrated to be lipid biomarkers mediating the MHO phenotype (Doumatey et al., 2016).”
BackgroundInfluentialSerum Fibroblast Growth Factor 23 Level and Liver Fat Content in MAFLD: A Community-Based Cohort
Cao, W., Xu, Y., Shen, Y., Wang, Y., Ma, X., & Bao, Y. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s328206 · Cited by 7
Korduner, J., Holm, H., Jujić, A., Melander, O., Pareek, M., Molvin, J., Råstam, L., Lindblad, U., Daka, B., Leósdóttir, M., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01559-9 · Cited by 7
“There is now an ongoing debate as to whether the term MHO should be avoided and instead be treated as a conceptual model to study mechanisms linking obesity to risk for or protection from cardiometabolic complications [28].”
BackgroundMoon, S.-G., & Park, B. (2022) · Journal of Preventive Medicine and Public Health · doi:10.3961/jpmph.22.286 · Cited by 9
Fatty acids as a direct regulator of aldosterone hypersecretion
Ling, G., Bruno, J., Albert, S. G., & Dhindsa, S. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111836 · Cited by 8
Pikó, P., Llanaj, E., Nagy, K., & Ádány, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065209 · Cited by 8
Bandres‐Meriz, J., Kunz, C., Havelund, J. F., Færgeman, N. J., Majali‐Martinez, A., Ensenauer, R. E., & Desoyé, G. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01295-4 · Cited by 11
“Second, in addition to BMI, defining obesity, and circulating maternal leptin as proxy for adiposity, we included maternal glucose, C-peptide and ISHOMA as metabolic exposures since a proportion of individuals with obesity may be metabolically ‘healthy’ [20].”
BackgroundInfluentialLeis, A. M., Mathis, M. R., Kheterpal, S., Zawistowski, M., Mukherjee, B., Pace, N. L., O’Reilly-Shah, V. N., Smith, J. A., & Karvonen-Gutierrez, C. A. (2023) · British Journal of Anaesthesia · doi:10.1016/j.bja.2023.04.001 · Cited by 6
Yoysungnoen, B., Srisawat, U., Piyabhan, P., Duansak, N., Sookprasert, N., Mathuradavong, N., Poomipark, N., Munkong, N., Tingpej, P., & Changtam, C. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1221935 · Cited by 7
Characterisation of body size phenotypes in a middle-aged Maltese population
Agius, R., Pace, N. P., & Fava, S. (2021) · Journal of Nutritional Science · doi:10.1017/jns.2021.74 · Cited by 10
“Unfortunately, to date, no consensus exists in the scientific literature((55)), with as many as thirty definitions being used((22)).”
BackgroundA simpler definition of MAFLD better predicts long-term all-cause mortality in American adults
Xie, J., Lu, L., Chen, Y., Xu, L., & Xu, C. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.01.015 · Cited by 7
“4 Considering that metabolically healthy obese individuals have a low risk of developing metabolic diseases [4], and waist circumference is widely regarded as an independent risk factor for MetS and also the only component of MetS that is associated with the presence of NAFLD and liver fibrosis [5, 6], we combined BMI…”
BackgroundEditorial: Adipose tissue dysfunction
Blüher, M., & Müller‐Wieland, D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.999188 · Cited by 8
“Among the biological mechanisms that link increased body fat mass to cardio-metabolic diseases, AT dysfunction is a major determinant of the individual obesity-associated risk (14, 15).”
BackgroundSelf-citationTranscriptomic meta-analysis characterizes molecular commonalities between psoriasis and obesity
Antonatos, C., Georgakilas, G. K., Εvangelou, Ε., & Vasilopoulos, Y. (2024) · Genes and Immunity · doi:10.1038/s41435-024-00271-w · Cited by 8
Alradi, M., Askari, H., Shaw, M., Bhavsar, J., Kingham, B. F., Polson, S. W., & Fancher, I. S. (2024) · Physiological Genomics · doi:10.1152/physiolgenomics.00080.2024 · Cited by 6
Bernal-Contreras, K. D., Berrospe-Alfaro, M., de Cárdenas-Rojo, R. L., Ramos-Ostos, M. H., Uribe, M., López-Méndez, I., & Juárez-Hernández, E. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1490277 · Cited by 7
Comparison of MRI head motion indicators in 40,969 subjects informs neuroimaging study design
Teo, T. W. J., Saffari, S. E., Chan, L. L., & Welton, T. (2024) · Scientific Reports · doi:10.1038/s41598-024-79827-9 · Cited by 8
Lim, C. G. Y., Özkan, B., Liang, Y., Chen, J., Yao, J., Khaing, N. E. E., Rooney, M. R., Ndumele, C. E., Tai, E. S., Coresh, J., et al. (2024) · Diabetes · doi:10.2337/db24-0184 · Cited by 11
Karpouzas, G. A., González-Gay, M. Á., Corrales, A., Myasoedova, E., Rantapää‐Dahlqvist, S., Sfikakis, P. P., Dessein, P., Hitchon, C. A., Pascual‐Ramos, V., Contreras-Yáñez, I., et al. (2025) · RMD Open · doi:10.1136/rmdopen-2025-005464 · Cited by 6
“Future studies should prioritise the use of tools such as DXA scans to better characterise body composition in RA and develop strategies to address sarcopenic obesity, particularly in ACPA-positive patients.”
Amino Acid Associations in Healthy and Unhealthy Obesity
Lim, G., Jarrell, Z. R., Go, Y., & Jones, D. P. (2025) · Journal of Nutrition · doi:10.1016/j.tjnut.2025.04.037 · Cited by 8
“These individuals have been referred to as “ metabolically healthy obese (MHO) ” [4].”
Patwari, P., Batra, N., Sen, K., Saha, A., Kumari, B., Basu, M., Mitra, S., Das, K., Kamilya, G., Baidya, A., et al. (2025) · Clinical Endocrinology · doi:10.1111/cen.15302 · Cited by 7
Wada, E., Hosono, H., Tanaka, M., Miyakawa, F., Ochi, K., Kohda, H., Tanno, S., Shimano, R., Ito, A., Kitaura, Y., et al. (2025) · The FASEB Journal · doi:10.1096/fj.202501121r · Cited by 6
NRAC controls CD36-mediated fatty acid uptake in adipocytes and lipid clearance in vivo
Singh, I., Onogi, Y., Menezes, F., Khasanova, D., Kang, L., Wang, C., Ruiz-Trave, J., Sharma, S., Khalil, A., Reichenbach, V. K., et al. (2025) · The EMBO Journal · doi:10.1038/s44318-025-00520-2 · Cited by 6
“Body composition and metabolic parameters were evaluated using standardized methods as previously detailed (Bluher, 2020; Kloting et al, 2010).”
Self-citationMolecular mechanisms underlying obesity-induced memory dysfunction: a comprehensive narrative review
Golkar, A., Razazpour, F., Dalfardi, M., & Baghcheghi, Y. (2025) · Physiology & Behavior · doi:10.1016/j.physbeh.2025.115119 · Cited by 8
Tănăsescu, M., Rosu, A.-M., Mincă, A., Grigorie, M.-M., Timofte, D., & Ionescu, D. (2026) · Life · doi:10.3390/life16020305 · Cited by 10
Dutta, G., Mishra, P., Mishra, S. P., & Badhai, J. (2026) · Onco · doi:10.3390/onco6030031 · Cited by 7
Genetic Effect on Body Mass Index and Cardiovascular Disease Across Generations
Sarnowski, C., Conomos, M. P., Vasan, R. S., Meigs, J. B., Dupuis, J., Liu, C., & Leong, A. (2023) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.122.003858 · Cited by 6
Bala, C. G., Rusu, A., Fronea, O. F. G., Benedek, T., Pop, C., Vijiiac, A. E., Stănciulescu, D., Dărăbanțiu, D., Román, G., & Dorobanţu, M. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20031736 · Cited by 5
Metabolic phenotypes and risk of end-stage kidney disease in patients with type 2 diabetes
Zhao, L., Zou, Y., Wu, Y., Cai, L., Zhao, Y., Wang, Y., Xiao, X., Yang, Q., Yang, J., Ren, H., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1103251 · Cited by 6
“MHO, MUNO, and MUO are reported to be transient phenotypes (13).”
BackgroundInfluentialMiao, K., Zhao, Y., & Xue, N. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29367 · Cited by 8
Cardiometabolic Characteristics of Obesity Phenotypes in Persons With HIV
Swartz, A. Z., Robles, M. E., Park, S., Esfandiari, H., Bradshaw, M. L., Koethe, J. R., & Silver, H. J. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae376 · Cited by 7
Shin, S., Kim, H. Y., Lee, J., Ryu, Y. J., Kim, J. Y., & Kim, J. H. (2024) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2346192.096 · Cited by 8
Lin, C., Guo, Z., Li, H., Lai, Z., Zhang, J., Xie, S., Tan, Y., & Jing, C. (2024) · Environmental Pollution · doi:10.1016/j.envpol.2024.125267 · Cited by 7
Association Between Metabolic and Obesity Phenotypes and Diabetes Risk in Children and Adolescents
Hao, H., Su, Y., & Feng, M. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s484639 · Cited by 8
“20,21 Therefore, maintaining a healthy body weight and simultaneously monitoring metabolic health is crucial for protecting against diabetes development.”
Zeng, X., Chen, R., Shi, D., Zhang, X., Su, T., Wang, Y., Hu, Y., He, M., Yu, H., & Shang, X. (2024) · Aging Cell · doi:10.1111/acel.14435 · Cited by 7
“In this context, it is essential to prioritize patients who would benefit most from weight loss interventions to reduce treatment costs, which requires tools to measure mortality and ORMs risk in individuals with overweight and obesity (Blüher, 2020).”
Zhou, X., Zou, Z., Liu, Y., Yan, Y., Wu, J., Zhou, G., & Li, M. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e41310 · Cited by 7
Chan, M., Yu, Y., Chang, P., Chen, T., Wong, H.-L., Huang, J.-H., Zhang, W., & Chen, S. (2024) · Electronics · doi:10.3390/electronics14010121 · Cited by 8
Loss of CTRP10 results in female obesity with preserved metabolic health
Chen, F., Sarver, D. C., Saqib, M., Vélez, L. M., Aja, S. M., Seldin, M. M., & Wong, G. W. (2025) · eLife · doi:10.7554/elife.93373.3 · Cited by 8
Kim, H. S., Lee, J., Cho, Y. K., Kim, E. H., Lee, M. J., Kim, H., Park, J., Lee, W. J., & Jung, C. H. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1184 · Cited by 5
PPARγ—A Factor Linking Metabolically Unhealthy Obesity with Placental Pathologies
Kwiatkowski, S., Kajdy, A., Stefanska, K. A., Bednarek-Jędrzejek, M., Dzidek, S., Tousty, P., Sokołowska, M., & Kwiatkowska, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313167 · Cited by 9
“The NHANES III study, carried out in the USA, revealed that 10% of the population with a normal BMI had an increased fat content [35,36].”
MethodOtt, F., Körner, C., Werner, K., Gericke, M. T., Liebscher, I., Lobsien, D., Radrezza, S., Shevchenko, A., Hofmann, U., Kratzsch, J., et al. (2022) · Cells · doi:10.3390/cells11101680 · Cited by 6
Molecular Mechanisms Involved in Insulin Resistance: Recent Updates and Future Challenges
Singh, A., Ghai, N., & Bedi, P. M. S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.104806 · Cited by 9
Sureka, B., George, T., Garg, M. K., Banerjee, M., Deora, S., Sukhla, R., Goel, A. D., Garg, P. K., Yadav, T., & Khera, P. S. (2022) · European Radiology · doi:10.1007/s00330-022-09009-6 · Cited by 6
Ramlugon, S., Levendal, R., & Frost, C. L. (2022) · Phytotherapy Research · doi:10.1002/ptr.7694 · Cited by 8
“ment of metabolic syndrome such as insulin resistance as glucose/lipid metabolism and insulin sensitivity are preserved (Ahmad & Zawatia, 2021; Blüher, 2020; Tsatsoulis & Paschou, 2020).”
BackgroundImmunometabolic aspects of chronic nonspecific inflammation in obesity
Skvortsova, O. V., Migacheva, N. B., & Михайлова, Е. Г. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-187 · Cited by 6
Barkas, F., Rizos, C. V., Liamis, G. L., Skoumas, I., Garoufi, A., Rallidis, L. S., Kolovou, G. D., Τζιόμαλος, Κ., Skalidis, E. I., Sfikas, G., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.01.005 · Cited by 8
Metabolically healthy obesity in adults with X-linked hypophosphatemia
Lecoq, A.-L., Schilbach, K., Rocher, L., Trabado, S., Briot, K., Herrou, J., Forbes, A., Garnier, A., Piketty, M., Bidlingmaier, M., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae089 · Cited by 8
Park, Y., Kim, M. K., & Liu, J. (2015) · Springer eBooks · doi:10.1007/978-3-031-40116-9_8 · Cited by 8
Different Curve Shapes of Fasting Glucose and Various Obesity-Related Indices by Diabetes and Sex
Wen, W., Wu, P.-Y., Huang, J., Tu, H., & Chen, S. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18063096 · Cited by 8
Treviño, S., Cortezano-Esteban, S., Hernández-Fragoso, H., Díaz, A., Vázquez‐Roque, R. A., Sarmiento-Ortega, V. E., Moroni-González, D., Pelayo, R., & Brambila, E. (2022) · Cytokine · doi:10.1016/j.cyto.2022.155868 · Cited by 6
Vermeiren, E., Eyck, A. V., Maele, K. V. D., Ysebaert, M., Makhout, S., Guchtenaere, A. D., Helvoirt, M. V., Tanghe, A., Naets, T., Vervoort, L., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.822962 · Cited by 6
“Nevertheless, this state of metabolic healthy obesity is a rather temporal stage before obesity-related comorbidities develop (68).”
BackgroundMartínez‐Sánchez, F. D., Diaz-Jarquin, A., Vargas-Abonce, V. P., Torres-Cuevas, J. L., Guerrero-Castillo, A. P., Medina‐Julio, D., Meza-Arana, C. E., Gulías-Herrero, A., & Gómez-Sámano, M. Á. (2022) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2022.100091 · Cited by 10
Álvarez-Monell, A., Subias-Gusils, A., Mariné-Casadó, R., Belda, X., Gagliano, H., Pozo, Ó. J., Boqué, N., Caimari, A., Armario, A., Solanas, M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-23464-7 · Cited by 7
Mas, M., Brindisi, M., & Chambaron, S. (2021) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2021.06.001 · Cited by 17
Stafeev, I., Sklyanik, I. A., Mamontova, E. D., Michurina, S. S., Shestakova, E. A., YAHYAEV, K., YURASOV, A., Masnikov, D., Sineokaya, M. S., Ratner, E. I., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.777589 · Cited by 6
“In this light, the search for new markers and mechanisms of the transition from non-diabetic obesity to severe insulin resistance and T2DM is of much interest to both clinic and basic research (3, 4).”
BackgroundMetabolically healthy obesity: it is time to consider its dynamic changes
Cho, Y. K., & Jung, C. H. (2022) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2022.4.e19 · Cited by 5
Associations of Metabolically Healthy Obesity and Retinal Age Gap
Zeng, X., Chen, R., Bulloch, G., Peng, Q., Cheng, C., He, M., Yu, H., & Zhu, Z. (2024) · Translational Vision Science & Technology · doi:10.1167/tvst.13.11.26 · Cited by 6
Jackson, A. T., Mazzola, J. J., & Loveless, J. P. (2025) · Occupational Health Science · doi:10.1007/s41542-025-00220-7 · Cited by 7
“…engage in physical activity and healthy eating often leads to changes in weight status, nutritional deficiencies, and dysregulation of metabolic and other neuroendocrine processes that promote health and well-being (Blüher, 2019, 2020; Drewnowski, 2020; Hruby & Hu, 2015; Yarborough et al., 2018).”
Liao, W., Yu, W., Zhao, Y., Ma, Z., & Xie, J. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1595862 · Cited by 5
“…lack of exercise unhealthy dietary habits, and other bad life patterns (10), college student groups lead to the accumulation of fat in the subcutaneous tissue, the accumulation of visceral fat intensifies (11), and the efficiency of energy metabolism decreases (12, 13), thus triggering obesity.”
Zeng, P., Jiang, C. S., Yin, H., Zhou, M., He, H., Yin, D., & Lin, F. (2025) · Nutrition Journal · doi:10.1186/s12937-025-01153-1 · Cited by 13
“Studies show that about one-third of overweight/obese individuals are metabolically healthy, without cardiovascular or diabetes risk [14, 15].”
Tang, M., Li, X., Ren, J., Yao, C., Liu, L., Li, X., Yuan, X., Zhao, J., Liu, B., Qiao, W., et al. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1597334 · Cited by 8
Tu, J., Wu, B., Chen, H., & Guo, Y. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01989-y · Cited by 8
“The TyG index evaluated insulin resistance using routine blood parameters, yet its limitations stemming from reliance on metabolic indicators prevented it from capturing the latent risks in metabolically healthy obese (MHO) individuals [26].”
Bao, L., & Duan, L. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1722731 · Cited by 5
“White adipose tissue and the infrapatellar fat pad are now recognized as active sources of local pro-inflammatory cytokines as well as adipokines, including TNF-α , IL-6, leptin, as well as resistin (28–30).”
Genetic architecture of obesity and advances in precision pharmacotherapy: a comprehensive review
Kavaja, F., Liehr, T., & Temaj, G. (2026) · Acta Biochimica Polonica · doi:10.3389/abp.2026.15484 · Cited by 6
“PRS stratify MHO/MUO transition risk, showing that high genetic burden accelerates the healthy-to-unhealthy conversion over time (~30%–50% MHO lose status/ decade) (Blüher, 2020).”
Sanghvi, G. V., Bishoyi, A. K., Joshi, K., Kaneriya, J. P., & Pattani, V. B. (2026) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2026.103422 · Cited by 7
Himbert, C., Warby, C. A., Gigic, B., Ose, J., Lin, T., Viskochil, R. H., Peoples, A. R., Ashworth, A., Schrotz‐King, P., Scaife, C. L., et al. (2022) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-22-0681 · Cited by 5
Zhu, L., Ziwei, S., Guan, Y., Meiyi, L., Zheng, Y., Ruoxi, Y. U., Qi, W., & Li, L. (2024) · PubMed Central · doi:10.19852/j.cnki.jtcm.20231110.005 · Cited by 9
Qin, Y., Chen, J., Qian, D., Li, Z., Zhang, L., & Ma, Q. (2024) · Journal of Nutrition · doi:10.1016/j.tjnut.2024.01.019 · Cited by 5
Metabolically healthy obesity and chronic kidney disease risk: exploring the dynamics
Güldan, M., Özbek, L., Topçu, A. U., Covic, A. C., & Kanbay, M. (2024) · Panminerva Medica · doi:10.23736/s0031-0808.24.05112-7 · Cited by 6
Wang, J., Apizi, A., Qiu, H., Tao, N., & An, H. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1442740 · Cited by 8
“One study found that MHO might be a transient phenotype (36).”
BackgroundHu, Y., Zhang, Y., Zhong, J., Wang, Y., Zhou, E., & Hong, F. (2024) · Preventive Medicine · doi:10.1016/j.ypmed.2024.108100 · Cited by 6
Ortiz, G. G. R., Maraver-Capdevila, L., & Granero, R. (2025) · Nutrients · doi:10.3390/nu17162651 · Cited by 6
Moreno‐Castellanos, N., Martín, A. Á., & Mora, G. M. (2021) · Salud UIS · doi:10.18273/saluduis.53.e:21009 · Cited by 8
Lehn‐Stefan, A., Peter, A., Machann, J., Schick, F., Randrianarisoa, E., Heni, M., Wagner, R. J., Birkenfeld, A. L., Fritsche, A., Schulze, M. B., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac091 · Cited by 7
Nguedjo, M. W., Ngondi, J. L., Ntentié, F. R., Azantsa, B. G. K., Javeres, M. N. L., & Oben, J. E. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11652 · Cited by 5
“Epidemiological data indicate that a significant proportion (10–30%) of individuals who are classified as obese are metabolically normal based on their metabolic profiles (Blüher, 2020).”
BackgroundWinkler, G., & Wittmann, I. (2023) · Orvosi Hetilap · doi:10.1556/650.2023.32680 · Cited by 7
Escobar, S., Peçanha, D. O., Duque, M., Duque, A. P., Crahim, V., Lorenzo, A. D., & Tibiriçá, E. V. (2023) · Microvascular Research · doi:10.1016/j.mvr.2023.104553 · Cited by 7
Invited Perspective: PFAS and the Childhood Obesity Phenotype—Challenges and Opportunities
Stratakis, N., & Vrijheid, M. (2023) · Environmental Health Perspectives · doi:10.1289/ehp12713 · Cited by 4
A simpler definition of MAFLD precisely predicts incident metabolic diseases: a 7-year cohort study
Xie, J., Xu, L., Huang, H., Chen, Y., Wang, J., Li, Y., Yu, C., & Xu, C. (2023) · Hepatology International · doi:10.1007/s12072-023-10558-1 · Cited by 6
Xiao, H., Shu, W., Li, M., Xu, L., Amaerjiang, N., Zunong, J., Vermund, S. H., Huang, D., Chong, M., & Hu, Y. (2023) · Nutrients · doi:10.3390/nu15133066 · Cited by 5
Kim, J., Choi, A., & Kwon, Y. H. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.10.003 · Cited by 5
Kidney and liver fat accumulation: from imaging to clinical consequences
Yıldız, A. B., Vehbi, S., Çöpür, S., Gürses, B., Siriopol, D. C., Karakaya, B. A. D., Hasbal, N. B., Tekin, B., Akyıldız, M., van Raalte, D. H., et al. (2023) · Journal of Nephrology · doi:10.1007/s40620-023-01824-4 · Cited by 7
“Metabolically healthy obesity, a newly identified category, constitutes a significant proportion of the overweight/obese population with considerable progression risk towards metabolic syndrome [2].”
Mustafina, S. V., Винтер, Д. А., Рымар, О. Д., Scherbakova, L. V., Sazonova, O. V., & Malutina, S. K. (2021) · Ateroscleroz · doi:10.52727/2078-256x-2021-17-52-61 · Cited by 5
Trang, N. T. T., Chiu, W., Feng, Y., Hsieh, S.-L., Tung, D. D., Chang, J., & Fong, T.-H. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/6007233 · Cited by 7
“Several studies have reported that visceral fat tissue and abnormal lipid metabolism are highly correlated with cardiovascular diseases, type 2 diabetes mellitus, and metabolic syndrome [1, 2].”
BackgroundZhao, K., Nie, L., Chin, G. M. J., Ye, X., & Sun, P. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1024750 · Cited by 7
“GSE169077 (USA), GSE117999 (USA), GSE11400 (USA), E-MTAB-6266 (UK), and PRJNA505578 (China) datasets were included.”
BackgroundMethodInfluential
Metadata
- Authors
- Blüher, M.
- Affiliations
- Helmholtz Munich (DE)
- Corresponding author
- Blüher, Matthias
- ORCID
- Blüher, Matthias
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2020-03-04
- Volume
- 41
- Issue
- 3
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC7098708
- OpenAlex
- W3009496837
- Cited by
- 1,090
- References
- 123
- Citations by year
- 2026: 197 · 2025: 222 · 2024: 213 · 2023: 162 · 2022: 155 · 2021: 105 · 2020: 35
- FWCI
- 86.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Endocrine Reviews (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Site cant be reached (submittedVersion, cc-by)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (209933838)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
- Keywords
- metabolically healthy obesity, obesity, cardiometabolic risk, type 2 diabetes, cardiovascular disease, insulin sensitivity, beta-cell function, ectopic fat, visceral fat, liver fat, leg fat, cardiorespiratory fitness, weight loss, obesity treatment, risk stratification
- MeSH terms
- Obesity, Metabolically Benign, Cardiometabolic Risk Factors, Diabetes Mellitus, Type 2, Humans, Insulin Resistance, Obesity, Metabolic Syndrome, Adiposity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.